Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis
NCT04605094 · AstraZeneca · PHASE2 · terminated · last registry update 2023-08-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study did not meet the primary endpoint.” | – | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL5RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, Benralizumab + fulvestrant or AIs) and PI3K inhibition (alpelisib) (NCT05966584)
- 2024-08-29Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Benralizumab + fulvestrant or AIs) and PI3K inhibition (alpelisib) (NCT05966584)
- 2024-07-22Phase 3 first posted: AstraZeneca, Benralizumab (NCT06512883)
- 2024-06-18Phase 3 first posted: AstraZeneca, Benralizumab (NCT06465485)
- 2024-04-24Results posted on the registry: AstraZeneca, Benralizumab + Placebo (NCT03186209)
- 2024-03-13Results posted on the registry: AstraZeneca, Benralizumab + Placebo and Benralizumab (NCT04612725)
- 2024-03-13Also stopped (terminated): AstraZeneca, Benralizumab + Placebo and Benralizumab (NCT04612725)
- 2024-01-08Also stopped (withdrawn): Charite University, Berlin, Germany, Fasenra Prefilled Syringe (NCT05528913)
- 2023-11-18Results posted on the registry: AstraZeneca, Benralizumab + Matching placebo (NCT04543409)
- 2023-11-18Also stopped (terminated): AstraZeneca, Benralizumab + Matching placebo (NCT04543409)
- 2023-05-18Results posted on the registry: AstraZeneca, Benralizumab (NCT04305405)
- 2023-01-20Phase 3 first posted: AstraZeneca, Benralizumab + Placebo (NCT05692180)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision